Genprex Receives Safety Review Committee Approval to Advance to Highest Dose Group in Phase 1 Portion of Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy in Combination With Tecentriq® in Extensive Stage Small Cell Lung Cancer
genprex獲得安全審查委員會批准,可以進入Acclaim-3臨床試驗階段1部分的最高劑量組,此試驗中結合Tecentriq在廣泛期小細胞肺癌中使用Reqorsa基因治療